Editor's note: Seeking Alpha is proud to welcome Joseph Heglin as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
Tivozanib Phase III Trial Analysis Announced
AVEO Pharmaceuticals Inc. (AVEO) just released results in their most recent clinical trials of their leading drug Tivozanib this week. This result showed a 44% improvement and 26% reduction in risk of progression of death compared to competitor, Sorafenib.